Recommendations for the Role of Extracorporeal Treatments in the Management of Acute Methanol Poisoning: A Systematic Review and Consensus Statement

Imagem de Miniatura
Arquivos
art_ROBERTS_Recommendations_for_the_Role_of_Extracorporeal_Treatments_in_2015.PDF (303.53 KB)
Citações na Scopus
115
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
ROBERTS, Darren M.
YATES, Christopher
MEGARBANE, Bruno
WINCHESTER, James F.
MACLAREN, Robert
GOSSELIN, Sophie
NOLIN, Thomas D.
LAVERGNE, Valery
HOFFMAN, Robert S.
GHANNOUM, Marc
Autor de Grupo de pesquisa
Extracorporeal Treatments
Citação
CRITICAL CARE MEDICINE, v.43, n.2, p.461-472, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Methanol poisoning can induce death and ""disability. Treatment includes the administration of antidotes (ethanol or fomepizole and folic/folinic acid) and consideration of extracorporeal treatment for correction of acidemia and/or enhanced elimination. The Extracorporeal Treatments in Poisoning workgroup aimed to develop evidence-based consensus recommendations for extracorporeal treatment in methanol poisoning. Design and Methods: Utilizing predetermined methods, we conducted a systematic review of the literature. Two hundred seventy-two relevant publications were identified but publication and selection biases were noted. Data on clinical outcomes and dialyzability were collated and a two-round modified Delphi process was used to reach a consensus. Results: Recommended indications for extracorporeal treatment: Severe methanol poisoning including any of the following being attributed to methanol: coma, seizures, new vision deficits, metabolic acidosis with blood pH.7.15, persistent metabolic acidosis despite adequate supportive measures and antidotes, serum anion gap higher than 24 mmol/L; or, serum methanol concentration 1) greater than 700 mg/L (21.8 mmol/L) in the context of fomepizole therapy, 2) greater than 600 mg/L or 18.7 mmol/L in the context of ethanol treatment 3) greater than 500 mg/L or 15.6 mmol/L in the absence of an alcohol dehydrogenase blocker; in the absence of a methanol concentration, the osmolal/ osmolar gap may be informative; or, in the context of impaired kidney function. Intermittent hemodialysis is the modality of choice and continuous modalities are acceptable alternatives. Extracorporeal treatment can be terminated when the methanol concentration is <200 mg/L or 6.2 mmol/L and a clinical improvement is observed. Extracorporeal Treatments in Poisoning inhibitors and folic/folinic acid should be continued during extracorporeal treatment. General considerations: Antidotes and extracorporeal treatment should be initiated urgently in the context of severe poisoning. The duration of extracorporeal treatment extracorporeal treatment depends on the type of extracorporeal treatment used and the methanol exposure. Indications for extracorporeal treatment are based on risk factors for poor outcomes. The relative importance of individual indications for the triaging of patients for extracorporeal treatment, in the context of an epidemic when need exceeds resources, is unknown. In the absence of severe poisoning but if the methanol concentration is elevated and there is adequate alcohol dehydrogenase blockade, extracorporeal treatment is not immediately required. Systemic anticoagulation should be avoided during extracorporeal treatment because it may increase the development or severity of intracerebral hemorrhage. Conclusion: Extracorporeal treatment has a valuable role in the treatment of patients with methanol poisoning. A range of clinical indications for extracorporeal treatment is provided and duration of therapy can be guided through the careful monitoring of biomarkers of exposure and toxicity. In the absence of severe poisoning, the decision to use extracorporeal treatment is determined by balancing the cost and complications of extracorporeal treatment to that of fomepizole or ethanol. Given regional differences in cost and availability of fomepizole and extracorporeal treatment, these decisions must be made at a local level.
Palavras-chave
acidosis, antidotes, consensus guidelines, Delphi process, dialysis, dialyzability, enhanced elimination, extracorporeal treatment, indications, intoxication, methanol, morbidity, mortality, poisoning, systematic review, triage
URI
https://observatorio.fm.usp.br/handle/OPI/26861
Referências
  1. Adanir T, 2005, EUR J ANAESTH, V22, P560, DOI 10.1017/S0265021505270941
  2. Adanir T, 2005, ANESTEZI DERGISI, V13, P127
  3. Akhtar J, 2008, CLIN TOXICOL, V46, P642
  4. Akhtar J, 2006, CLIN TOXICOL, V44, P714
  5. [Anonymous], 1946, ACTA MED SCAND, V125, P117
  6. Anseeuw K, 2008, EUR J EMERG MED, V15, P107, DOI 10.1097/MEJ.0b013e3282f3c13b
  7. Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
  8. Barceloux DG, 2002, J TOXICOL-CLIN TOXIC, V40, P415
  9. Bebarta VS, 2006, AM J EMERG MED, V24, P725, DOI 10.1016/j.ajem.2006.03.004
  10. BENNETT IL, 1953, MEDICINE, V32, P431, DOI 10.1097/00005792-195312000-00002
  11. BERENDT RC, 1987, J CRIT CARE, V2, P181, DOI 10.1016/0883-9441(87)90005-0
  12. BERGERON R, 1982, NEW ENGL J MED, V307, P1528
  13. Brent J, 2001, NEW ENGL J MED, V344, P424, DOI 10.1056/NEJM200102083440605
  14. Bronstein AC, 2012, CLIN TOXICOL, V50, P911, DOI 10.3109/15563650.2012.746424
  15. Burns AB, 1998, AM J EMERG MED, V16, P538, DOI 10.1016/S0735-6757(98)90014-6
  16. Burns MJ, 1997, ANN EMERG MED, V30, P829, DOI 10.1016/S0196-0644(97)70060-X
  17. CHEW WB, 1946, JAMA-J AM MED ASSOC, V130, P61, DOI 10.1001/jama.1946.02870020005002
  18. Coulter CV, 2011, CLIN TOXICOL, V49, P900, DOI 10.3109/15563650.2011.630320
  19. Coulter CV, 2011, CLIN PHARMACOKINET, V50, P245, DOI 10.2165/11584250-000000000-00000
  20. EKINS BR, 1985, WESTERN J MED, V142, P337
  21. Ellsworth H, 2011, CLIN TOXICOL, V49, P515
  22. Elwell RJ, 2004, AM J EMERG MED, V22, P126, DOI 10.1016/j.ajem.2003.12.017
  23. Fadnes H O, 1985, Lakartidningen, V82, P116
  24. Fitch K, 2011, RAND UCLA APPROPRIAT
  25. FRENIA ML, 1993, ANN EMERG MED, V22, P1919, DOI 10.1016/S0196-0644(05)80424-X
  26. Ghannoum M, 2014, SEMIN DIALYSIS, V27, P395, DOI 10.1111/sdi.12237
  27. Ghannoum M, 2011, ADV CHRONIC KIDNEY D, V18, P160, DOI 10.1053/j.ackd.2011.01.008
  28. GONDA A, 1978, AM J MED, V64, P749, DOI 10.1016/0002-9343(78)90513-2
  29. Graw M, 2000, ARCH TOXICOL, V74, P313, DOI 10.1007/s002040000107
  30. Hantson P, 2005, HUM EXP TOXICOL, V24, P55, DOI 10.1191/0960327105ht503oa
  31. Hassanian-Moghaddam H, 2007, HUM EXP TOXICOL, V26, P583, DOI 10.1177/0960327106080077
  32. Hassanian-Moghaddam H, 2013, P ASIA PACIFIC ASS M, V49
  33. Hovda KE, 2008, HUM EXP TOXICOL, V27, P539, DOI 10.1177/0960327108095992
  34. Hovda KE, 2005, J INTERN MED, V258, P181, DOI 10.1111/j.1365-2796.2005.01521.x
  35. Hovda KE, 2005, CLIN TOXICOL, V43, P221, DOI 10.1081/CLT-200058936
  36. Hovda KE, 2004, INTENS CARE MED, V30, P1842, DOI 10.1007/s00134-004-2373-7
  37. Hunderi Odd Helge, 2004, Tidsskr Nor Laegeforen, V124, P3199
  38. Hunderi OH, 2006, SCAND J UROL NEPHROL, V40, P70, DOI 10.1080/00365590500190755
  39. Isaacs R, 1920, J AMER MED ASSOC, V75, P718
  40. Iseki Ken, 2009, Chudoku Kenkyu, V22, P238
  41. JACOBSEN D, 1982, ACTA MED SCAND, V212, P5
  42. Jacobsen D, 1997, J TOXICOL-CLIN TOXIC, V35, P127, DOI 10.3109/15563659709001182
  43. JACOBSEN D, 1983, SCAND J CLIN LAB INV, V43, P377
  44. JACOBSEN D, 1983, ACTA MED SCAND, V214, P409
  45. JACOBSEN D, 1986, MED TOXICOL ADV DRUG, V1, P309, DOI 10.1007/BF03259846
  46. KANE RL, 1968, ARCH ENVIRON HEALTH, V17, P119, DOI 10.1080/00039896.1968.10665199
  47. Kerns W, 2002, J TOXICOL-CLIN TOXIC, V40, P137, DOI 10.1081/CLT-120004401
  48. Kostic MA, 2003, J TOXICOL-CLIN TOXIC, V41, P793, DOI 10.1081/CLT-120025344
  49. Krasowski MD, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-1
  50. Kute VB, 2012, SAUDI J KIDNEY DIS T, V23, P37
  51. Lavergne V, 2012, CLIN TOXICOL, V50, P403, DOI 10.3109/15563650.2012.683436
  52. Liu JJ, 1998, J TOXICOL-CLIN TOXIC, V36, P175, DOI 10.3109/15563659809028937
  53. Lynd LD, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-5
  54. MAHIEU P, 1989, HUM TOXICOL, V8, P135, DOI 10.1177/096032718900800209
  55. MARCAURELE J, 1960, J CLIN INVEST, V39, P802, DOI 10.1172/JCI104098
  56. MCCORMICK MJ, 1990, ANN EMERG MED, V19, P639, DOI 10.1016/S0196-0644(05)82467-9
  57. MCCOY HG, 1979, AM J MED, V67, P804, DOI 10.1016/0002-9343(79)90738-1
  58. MCMARTIN KE, 1980, AM J MED, V68, P414, DOI 10.1016/0002-9343(80)90113-8
  59. MEATHERALL R, 1990, CLIN CHEM, V36, P2004
  60. Megarbane B, 2001, INTENS CARE MED, V27, P1370, DOI 10.1007/s001340101011
  61. Meyer RJ, 2000, NEW ZEAL MED J, V113, P11
  62. Nelson L., 2010, GOLDFRANKS TOXICOLOG
  63. NOLLASALAS J, 1995, MED CLIN-BARCELONA, V104, P121
  64. OSTERLOH JD, 1986, ANN INTERN MED, V104, P200, DOI 10.7326/0003-4819-104-2-200
  65. Paasma R, 2007, CLIN TOXICOL, V45, P152, DOI 10.1080/15563650600956329
  66. Paasma R, 2012, CLIN TOXICOL, V50, P823, DOI 10.3109/15563650.2012.728224
  67. Paasma Raido, 2009, BMC Clin Pharmacol, V9, P5, DOI 10.1186/1472-6904-9-5
  68. PALATNICK W, 1995, ANN EMERG MED, V26, P202, DOI 10.1016/S0196-0644(95)70152-4
  69. PFISTER AK, 1966, J AMER MED ASSOC, V197, P1041
  70. PHANG PT, 1988, CRIT CARE MED, V16, P137, DOI 10.1097/00003246-198802000-00008
  71. ROE O, 1950, Q J STUD ALCOHOL, V11, P107
  72. ROEGGLA G, 1993, AM FAM PHYSICIAN, V48, P731
  73. SCHREINER GE, 1970, T AM SOC ART INT ORG, V16, P544
  74. Sharma R, 2012, OPTOMETRY VISION SCI, V89, P178, DOI 10.1097/OPX.0b013e31823ee128
  75. Sivilotti M, 1998, CLIN TOXICOL PHILA, V36, P451
  76. Spillum BJ, 2003, CLIN TOXICOL, V41, P397
  77. SWARTZ RD, 1981, MEDICINE, V60, P373, DOI 10.1097/00005792-198109000-00005
  78. Teo S. K., 1996, Singapore Medical Journal, V37, P485
  79. Unsal A, 2012, NEPHRO UROL MON, V4, P366
  80. Vares M, 2012, MED INTENSIVA, V36, P379, DOI 10.1016/j.medin.2011.09.013
  81. Wallace EA, 2009, CLIN TOXICOL, V47, P239, DOI 10.1080/15563650802498781
  82. Waring WS, 2010, CLIN TOXICOL, V48
  83. Zakharov S, 2014, KIDNEY INT, V86, P199, DOI 10.1038/ki.2014.60

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/12